Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are ...

The following is a summary of “Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and ...

Phase 3 data support pyrotinib plus trastuzumab and docetaxel “as a well-established and effective treatment strategy,” according to Binghe Xu, MD.

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...